Načítá se...
First-line treatment of metastatic melanoma: role of nivolumab
Historically, the median overall survival of metastatic melanoma patients was less than 1 year and long-term survivors were rare. Recent advances in therapies have dramatically shifted this landscape with increased survival rates and the real possibility that long-term disease control is achievable....
Uloženo v:
| Vydáno v: | Immunotargets Ther |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Dove Medical Press
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5315343/ https://ncbi.nlm.nih.gov/pubmed/28243579 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/ITT.S110479 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|